TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03279458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Linshom Respiratory Monitoring Device
Description: Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted wth the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air. The excursions of the thermistor tracings (from valley to peak) will be recorded by the Linshom device and displayed continuously on a laptop monitor in a waveform. The tidal volume will also be measured by the ventilator and the data downloaded in a Compact Flash card.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Linshom Respiratory Monitoring Device
Description: Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted wth the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air. The excursions of the thermistor tracings (from valley to peak) will be recorded by the Linshom device and displayed continuously on a laptop monitor in a waveform. The tidal volume will also be measured by the ventilator and the data downloaded in a Compact Flash card.
Study: NCT01512888

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CL20-i4-EF1α-hγc-OPT
Description: Participants will undergo infusion with autologous CD34+ bone marrow cells transduced with a lentiviral vector that contains a normal copy of the human γc gene.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given intravenously (IV).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMacs
Description: Isolation and purification of CD34+ stem cells will be done after the unmodified frozen backup is obtained and in accordance with our FDA IND and in accordance with the CliniMacs manual of operations.
Study: NCT06018090

Intervention type: OTHER
Intervention: The presence and rate of MES measured by TCD monitoring
Description: TCD monitoring within 24 hours from the last known well time. Bilateral M1 segments of middle cerebral artery were insonated at a single depth with 2-MHz transducers secured by a probe-holder.
Study: NCT04224116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: to receive tranexamic acid (25mg/kg) in bolus at induction followed by 2mg/kg/h in continuous infusion until the end of the act.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SSI
Description: Serum Salin isotonic injected
Study: NCT00063453

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: vitamin E (400 IU/day all rac-α-tocopheryl acetate)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: vitamin E (400 IU/day all rac-α-tocopheryl acetate)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium
Description: selenium (200 μg/d L-selenomethionine)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium
Description: selenium (200 μg/d L-selenomethionine)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E placebo
Description: placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin E placebo
Description: placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium placebo
Description: placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Selenium placebo
Description: placebo
Study: NCT01502891

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid
Description: The decision aid, Depression Medication Choice, uses plain language and is designed to enhance patient understanding and satisfy the International Patient Decision Aid Standards (IPDAS) requirements for a safe and unbiased decision aid.
Study: NCT03955315

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDCT
Description: Discogenic Cells + Sodium Hyaluronate Vehicle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDCT
Description: Discogenic Cells + Sodium Hyaluronate Vehicle

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Needle puncture under the muscular layer in front of the intervertebral disc
Study: NCT02145390

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral Resection of the Bladder Tumor & Cystoscopy
Description: TURBT and Cystoscopy will be performed by the participating urologist prior to start of neoadjuvant chemotherapy, per the study protocol:~* Cystoscopic evaluation~* Bimanual examination under anesthesia,~* Transurethral resection of the bladder tumor,~* Biopsy of the prostatic urethra including both mucosa and stroma using a resection loop.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: For subjects with complete response to neoadjuvant chemotherapy. Subjects will receive 25 daily fractions (5 weeks) of radiation therapy for 5 days a week (Monday to Friday) except on weekends or holidays, when remaining fractions will be added to the end of treatment. The overall schema is for IMRT based radiation to the entire bladder, prostate (in men) and the pelvic lymph nodes:~* Pelvic lymph nodes: 45 Gy in 25 fractions at 1.8 Gy per fraction.~* Whole bladder and prostate: 50 Gy in 25 fractions at 2.0 Gy per fraction.~* Tumor boost area: 60-65 Gy in 25 fractions at 2.4-2.6 Gy per day~* Final boost dose will be determined at the discretion of the treating physician based on normal tissue exposure and volume.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanded Prostate Cancer Index Composite Short Form 12
Description: Quality of life questionnaire to be administered to subjects at intervals defined by the study protocol.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: International Prostate Symptom Score
Description: Quality of life questionnaire to be administered to subjects at intervals defined by the study protocol.
Study: NCT03820232

Intervention type: DEVICE
Intervention: temperature monitoring
Description: In every patient observed in this prospective observational study, body core temperature will be contemporaneously monitored through the oesophageal probe and the heated controlled servo sensor. Both are routinely used for this purpose in clinical practice
Study: NCT04696198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy Intervention
Description: Manual Therapy Interventions to improve range of motion and decrease pain

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: standard care
Study: NCT01813279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the cell therapy
Description: the reinjection of autologous stromal vascular fraction of adipose tissue issue on the fingers of patients with scleroderma.
Study: NCT01141608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vigorous Intensity High Dose Exercise
Description: Participants randomized to the exercise condition will begin with supervised exercise sessions 3 times per week during the 12-week acute phase of the study. Supervised sessions will be conducted as one-on-one (i.e., individual) sessions. Vigorous intensity high dose exercise will be prescribed at a dose of 12 kcal/kg/week (KKW), with intensity ranging from 70-85% maximal heart rate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Education Intervention
Description: Participants randomized to the health education condition will also begin with visits 3 times per week during the 12-week acute phase. The health education sessions will be conducted as one-on-one (i.e., individual) sessions. Health education sessions will consist of information on health-related topics distributed via methods such as didactics, audio and video materials, and written materials.
Study: NCT01276834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: comparison of everolimus-based and CNI-based immunosuppression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: everolimus
Description: comparison of everolimus-based and CNI-based immunosuppression
Study: NCT03261193

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: ITM + Sham QLB
Description: Sham subcutaneous non-anesthetic infiltration with saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITM + Bupivacaine QLB
Description: QL plane block with local anesthesia
Study: NCT03504553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noise reduction
Description: All activity will cease when the patient enters the operating room and nonessential personnel will be removed. Ambient lighting will be reduced and communication devices muted.
Study: NCT00080262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Solution, IV, 40 mg/m2, every 21 days, extended, until PD or discontinued for other reasons.
Study: NCT03907345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure
Description: The exposure session comprises a hierarchy of 7 steps, reaching from (1) holding a glass with the spider 30cm in from the body / face, to (7) letting the spider walk on the arm. The exposure session has a duration of 120 minutes. Prior to the exposure, participants receive psychoeducation on anxiety and phobias. A house spider (Tegenaria domestica) is used for the exposure.
Study: NCT04311957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of boosted PI
Description: Continuation of the same second-line regimen taken prior to entry:~LPVr 400 mg/100 mg BID or ATVr 300 mg/100 mg QD + 2 NRTIs
Study: NCT04650139

Intervention type: PROCEDURE
Intervention: PCI - percutaneous coronary intervention
Description: percutaneous coronary intervention

Intervention type: PROCEDURE
Intervention: PCI - percutaneous coronary intervention
Description: percutaneous coronary intervention
Study: NCT02075073

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB3

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU sourced Herceptin®
Study: NCT04311957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: Single-tablet, fixed dose combination of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/F/TAF) administered orally, once daily.
Study: NCT04055870

Intervention type: PROCEDURE
Intervention: EUS-guided liver biopsy at MDMC
Description: Endoscopic ultrasound (EUS) guided liver biopsy sampling is emerging as an alternative to the aforementioned approaches that offers several advantages, including decreased sampling variability and procedure-related complications.
Study: NCT03534219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EarPopper
Description: The EP device is 510(K) regulated (510(K) Number K073401) as a non-surgical, non-drug related treatment for middle ear pressure problems. The device is based on the Politzer Maneuver, and works by opening the Eustachian tube by delivering a safe, constant stream of air into the nasal cavity. In clinical studies funded by the National Institutes of Health (Grant#: 5R44DC003613-03), the EarPopper has proven to be effective in reducing chronic middle ear effusions. By regularly aerating the middle ear, we hypothesize that the EarPopper device will be an effective prophylactic measure to reduce incidence of AOM in children with recurrent OM. The device delivers a jet of air pressure from the nozzle at 5.2PSI, at a volume velocity of 1,524mL/min.
Study: NCT02603900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: 15 ml 0.5% Ropivicaine for primary adductor canal block under ultrasound guidance and 0.2% Ropivicaine infusion 10 ml/hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine
Description: 20 ml bupivacaine ( Marcaine 0.25% with epinephrine 1:200000, Hospira Inc. Lake Forest, IL) diluted with 40 ml of normal saline injected intraoperatively into the knee joint before closure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Adductor Canal Catheter
Description: Sham catheter placement via ultrasound-guided adductor canal block and 10ml/hr saline via OnQ Pump via continuous catheter in adductor canal.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Catheter
Description: Catheter placed in adductor canal via ultrasound guidance and continuous infusion via OnQ pump.
Study: NCT02837159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth application
Description: Dietary and physical activity recommendations trough a mobile application
Study: NCT03349307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thin Convex Probe Endobronchial Ultrasound (TCP-EBUS)
Description: Patients scheduled for a lobectomy will be recruited to this study and approached for informed consent. At the time of surgery, once the lobe has been removed, the TCP-EBUS will be inserted through a bronchial stamp for brief operability evaluations and image acquisition. Once this data has been captured standard of care will continue.
Study: NCT04377659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive Tocilizumab 8 mg/kg i.v. at enrollment. Dose will be capped at 800 mg per infusion. If there is no improvement or toxicity, a second dose can be given 24 hrs to 5 days later.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive Tocilizumab 8 mg/kg i.v. at enrollment. Dose will be capped at 800 mg per infusion. If there is no improvement or toxicity, a second dose can be given 24 hrs to 5 days later.
Study: NCT02538991

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bulkamid
Description: Urethral injections will be performed policlinically under local anesthesia (10 ml lidocain, two injections on both sides of the urethra). The Bulkamid-injections will be transurethral four injections (0.2 - 1ml) in locations ten, two and five and seven o'clock within 0.5 to 1 cm from the bladder - urethra junction.~Additional injections will be avoided and can be injected only if the first injections fail. After the operation the patient urinates to empty the bladder. The PVR is checked after the treatment with ultrasound simultaneously with evaluation of stability of the Bulkamid-injections. The treatment will be photographed as before and after still pictures for later evaluation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tension-free Vaginal Tape
Description: TVT will be performed under local anesthesia (70 - 100 ml 0.25% prilocain cum epinephrine) with i.v. pain medication phentanyl two doses and more on request. Operation will be performed with TVT-Exact® kit. Operation can be performed policlinically or in an operation theatre depending on the patient's medical condition. Cystoscopy will be performed after the set of tapes. A cough stress test with 250 to 300 ml bladder fulfillment will show the right tension of the tape. Before the operation a prophylactic antibiotic of Cefuroxime 1.5 g i.v will be given (Dalacin 900 mg i.v in cases of allergy to penicillin). The patient can go home after 2 to 4 hours follow-up, when PVR is under 150 ml. A sick leave of 5 days is recommended.
Study: NCT03024567

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Salt
Description: 10 capsules daily for 14 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 capsules daily for 14 days
Study: NCT02753881

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: whole liver lobe cTACE doxorubicin
Description: Doxorubicin CTACE administered in a whole liver lobe manner.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: superselective cTACE doxorubicin
Description: Doxorubicin CTACE administered in a super-selective (close to the tumor) manner.
Study: NCT00506675

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patching
Description: 42 hours per week of patching

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: daily atropine (1%)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patching
Description: two hours of daily patching for 4 weeks, then no treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: once weekly atropine for 4 weeks, then no treatment
Study: NCT02763618

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurofeedback
Description: Neurofeedback theta/beta ratio training. See 'Neurofeedback theta/beta ratio training' in detailed study description.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurofeedback
Description: Neurofeedback theta/beta ratio training. See 'Neurofeedback theta/beta ratio training' in detailed study description.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Neurofeedback training
Description: The placebo training will be a previously recorded Neurofeedback session of a participant in group A
Study: NCT02574091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% icotinib hydrochloride cream
Description: Topical administration for twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% icotinib hydrochloride cream
Description: Topical administration for twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% icotinib hydrochloride cream
Description: Topical administration for twice daily.
Study: NCT04390828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery Meditation
Description: the guided image meditation invention program of the intervention measures of this study include four important elements: 1) Meditation exercises: the exercises to adjust the body and mind through specific attention, so that people gradually feel the state of relaxation through practice; (2) Guided image: the simple visualization and use of mental images produced by imagination as a form of psychotherapy, images come from natural scenes (e.g., forests and mountains, streams and oceans), positive feelings and emotions are generated through psychological imagination to induce psychological and physiological relaxation state; (3) Music aids: reaching a relaxed state with comfortable and slow background music; (4) Breathing relaxation training: the patient is taught to take abdominal breathing to divert attention and stimulate the parasympathetic nervous system to achieve muscle relaxation. The entire intervention process takes about 15 to 20 minutes, 2 times a day.
Study: NCT00392639

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comparison of 2 cooling procedures
Description: Comparison of 2 cooling procedures
Study: NCT02563756

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unicompartmental knee replacement
Description: Participants with a medial gonarthritis are operated with a medial unicompartmental prosthesis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee replacement
Description: Participants with a medial gonarthritis are operated with a total knee replacement
Study: NCT00185523

Intervention type: PROCEDURE
Intervention: Allogeneic hematopoietic cell transplantation
Study: NCT02574091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% icotinib hydrochloride cream
Description: Topical administration for twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical administration for twice daily.
Study: NCT02075073

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US sourced Herceptin®
Study: NCT02574091

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical administration for twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical administration for twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical administration for twice daily.
Study: NCT00501839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Study: NCT01706328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 Inhalation Powder NDPI
Description: Subjects randomized to the FF/VI Inhalation Powder Novel Dry Powder Inhaler (NDPI) arm will receive a single inhalation of 100 mcg FF and 25 mcg VI via NDPI every morning for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS
Description: Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of 250 mcg Fluticasone Propionate and 50 mcg Salmeterol via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Inhalation Powder NDPI
Description: Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of placebo inhalation powder via NDPI every morning for 12 weeks.
Study: NCT01706328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Inhalation Powder ACCUHALER/DISKUS
Description: Subjects randomized to the FF/VI Inhalation Powder NDPI arm will receive a single inhalation of placebo inhalation powder via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol as needed
Description: Salbutamol inhalation powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol as needed
Description: Salbutamol inhalation powder
Study: NCT02790177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NORMAL SALINE
Study: NCT02110251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Therapy
Study: NCT02850835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Decision Aid
Description: A video decision aid was developed inform patients about pelvic organ prolapse, to include female anatomy, and treatment options.
Study: NCT06443827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine Sulfate
Description: intravenous amantadine sulphate at a single daily dose of 200 mg or physiological saline (0.9% NaCl solution)
Study: NCT03798314

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study: NCT02078258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABMT
Description: During a two-week period, 8 sessions of a modified dot probe task for attentional bias modification training (ABMT) condition, 8 sessions of a classic dot probe task for placebo training (PT) condition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ABMT
Description: During a two-week period, 8 sessions of a modified dot probe task for attentional bias modification training (ABMT) condition, 8 sessions of a classic dot probe task for placebo training (PT) condition.
Study: NCT01822444

Intervention type: OTHER
Intervention: Biomarker analysis